The Drug Enforcement Administration has issued a final rule that, effective April 5, will permanently place the synthetic opioid brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever their existence is possible, into schedule I of the Controlled Substances Act.

This rule makes permanent the administrative, civil, and criminal sanctions and regulatory controls applicable to schedule I substances on persons who import, export, manufacture, distribute, possess, engage in research on, or conduct instructional activities with this substance, which include the following.

- any person who engages in the above activities with respect to this substance must be registered with the DEA to conduct such activities

- all importation and exportation of this substance must be in compliance with 21 USC 952, 953, 957, and 958 and in accordance with 21 CFR part 1312

- all labels, labeling, and packaging for commercial containers of this substance must comply with the requirements of 21 CFR part 1302

- any activity involving this substance that is not authorized by, or is in violation of, the CSA is unlawful and potentially subject to administrative, civil, and/or criminal sanctions

Copyright © 2024 Sandler, Travis & Rosenberg, P.A.; WorldTrade Interactive, Inc. All rights reserved.

ST&R: International Trade Law & Policy

Since 1977, we have set the standard for international trade lawyers and consultants, providing comprehensive and effective customs, import and export services to clients worldwide.

View Our Services 


Cookie Consent

We have updated our Privacy Policy relating to our use of cookies on our website and the sharing of information. By continuing to use our website or subscribe to our publications, you agree to the Privacy Policy and Terms & Conditions.